Diffuse Large B-Cell Lymphoma, NOS · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | None |
| ID | IND-IATROGENIC-ANTI-TNF-LYMPHOMA-PREVENTION-SURVEILLANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-NCCN-BCELL-2025 SRC-NCCN-SKIN-2025 |
Notes
STUB — v0.3 iatrogenic pilot (anti-TNF biologic chronic exposure with modest lymphoma signal in pediatric / young-adult IBD). Two-Clinical-Co-Lead signoff queued. Key framing: anti-TNF monotherapy is at population cancer background; combination with thiopurine is the meaningful axis with HSTCL signal in young men.
Used By
No reverse references found in the YAML corpus.